Clinical Trial Update: 100% VS 80% Of Pegasys In Koreans With Chronic Hepatitis C (CHC) [Phase 4]

View source ↗

Summary

A Phase 4 trial in Korean patients with chronic hepatitis C reported sustained virologic response rates of 100% versus 80% for Pegasys.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: The Catholic University of Korea | Conditions: Sustained Virologic Response, IL28B Polymorphism | Phase 4 | Status: COMPLETED | Results posted: 2013-03-08